Clinical Trial Update: Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females [Phase 3]

View source ↗

Summary

Phase 3 trial assessing immunogenicity and safety of 4-valent and 9-valent HPV recombinant vaccine in Chinese healthy females; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Cin 1
• Cin 2
• Cin 3
• Genital Warts
• Vaginal Cancer
• Vin 1
• Vin 2
• Vin 3
• Vulvar Cancer

Drugs mentioned

• HPV recombinant vaccine (4-valent) / HPV recombinant vaccine (9-valent)

Snippet

Sponsor: Shanghai Bovax Biotechnology Co., Ltd. | Conditions: Cervical Cancer, Vulvar Cancer | Phase 3 | Status: COMPLETED